The global genitourinary syndrome of menopause (GSM) sector was valued at USD 1.60 billion in 2025 and is projected to reach USD 1.72 billion in 2026 and approximately USD 3.21 billion by 2035, expanding at a CAGR of 7.20% from 2026 to 2035.
Growth is being driven by increasing awareness of menopausal health, rising demand for effective symptom management, wider access to therapies, and growing interest in non-hormonal and minimally invasive treatment options.
Download a Sample Report: https://www.precedenceresearch.com/sample/8115
Genitourinary Syndrome of Menopause Treatment Overview
Genitourinary syndrome of menopause (GSM) refers to a group of vulvovaginal and urinary symptoms associated with declining estrogen levels after menopause. Common symptoms include vaginal dryness, irritation, discomfort during intercourse, urinary frequency, and burning.
Treatment options include vaginal estrogen therapies, oral selective estrogen receptor modulators, vaginal DHEA, non-hormonal moisturizers and lubricants, and energy-based procedures. The treatment landscape is expanding as healthcare professionals and patients increasingly recognize that GSM can be managed effectively rather than being accepted as an unavoidable part of aging.
Why Is Genitourinary Syndrome of Menopause Treatment Gaining Momentum?
Rising awareness is one of the strongest factors supporting growth. Menopause health is receiving greater attention through healthcare campaigns, educational programs, women’s health platforms, and improved communication between patients and healthcare professionals.
At the same time, the growing postmenopausal population is increasing the number of women seeking treatment for persistent symptoms. Better access to gynecological services and the expansion of retail and online pharmacies are also making supportive products easier to obtain.
Another important factor is the increasing availability of treatment choices. Women can select therapies based on symptom severity, medical history, treatment preferences, and physician recommendations, supporting more individualized care.
AI Is Transforming Genitourinary Syndrome of Menopause Care
Artificial intelligence is creating new opportunities in genitourinary syndrome of menopause treatment by supporting personalized care, symptom tracking, and clinical decision-making. AI-enabled health platforms can analyze patient-reported symptoms and treatment histories to identify patterns and support more informed consultations.
Machine learning can also help researchers evaluate clinical data and identify factors associated with treatment response. Digital health applications may further support long-term symptom monitoring, appointment management, and patient education, improving engagement with menopause care.
Powerful Trends Shaping Genitourinary Syndrome of Menopause Treatment
Growing Awareness of Menopause Health
Greater awareness is encouraging women to discuss symptoms that were previously overlooked or considered a normal consequence of aging. Improved education is leading to earlier consultations and stronger demand for treatment.
Rise of Non-Hormonal Options
Some women prefer non-hormonal approaches because of personal preferences or medical considerations. Moisturizers, lubricants, DHEA-based therapies, and emerging device-based procedures are expanding available treatment choices.
Advanced Energy-Based Procedures
Energy-based technologies using controlled laser or radiofrequency energy are attracting attention as minimally invasive approaches. Research and clinical guidance continue to shape their appropriate use, creating opportunities for innovation.
Digital and Home-Based Care
Online consultations, digital health applications, and home-use products are improving access to support and symptom management. These channels are particularly valuable for women seeking privacy and convenience.
Vaginal Estrogen Therapies Remain the Leading Treatment
The vaginal estrogen therapies segment accounted for 38.60% of the share in 2025. These therapies directly address estrogen deficiency-related tissue changes and are available in forms such as creams, tablets, and vaginal rings.
Their established clinical use and ability to relieve common GSM symptoms continue to support strong adoption. The energy-based devices and procedures segment is expected to experience rapid growth through 2035 as interest increases in non-hormonal treatment alternatives and minimally invasive approaches.
Prescription Therapies Maintain Strong Adoption
The prescription therapies segment held 56.70% of the share in 2025. Prescription-based treatment remains important because healthcare professionals can evaluate symptom severity, medical history, and treatment suitability before recommending therapy.
The device-based procedures segment is expected to grow at the fastest rate during the forecast period. These approaches use controlled energy to target vaginal tissue and are attracting interest from women seeking alternatives to conventional medication-based treatment.
Vaginal Dryness and Irritation Lead the Indication Landscape
The vaginal dryness and irritation segment held the largest share of 34.60% in 2025. These are among the most frequently reported symptoms associated with GSM and can affect daily comfort, sexual health, and quality of life.
The urinary symptoms segment is expected to grow rapidly as awareness of the connection between menopause-related estrogen decline and lower urinary tract symptoms increases. Greater recognition of these symptoms is encouraging more women to seek professional care.
Retail Pharmacies Remain a Major Distribution Channel
The retail pharmacy segment accounted for 44.60% of the share in 2025. Local pharmacies provide convenient access to moisturizers, lubricants, and prescription products while also offering opportunities for pharmacist guidance.
The online pharmacy and e-commerce segment is expected to grow rapidly. Online channels offer privacy, home delivery, product comparison, and access to products that may not be readily available through local stores. These benefits are particularly relevant for intimate health products.
Hospitals Continue to Lead End Use
The hospitals segment held 46.80% of the share in 2025. Hospitals provide access to gynecologists, diagnostic facilities, specialist consultations, and multiple treatment options in one setting.
The home care and self-care segment is expected to grow at a CAGR of 10.30%. Women with mild or manageable symptoms increasingly use moisturizers, lubricants, and other supportive products at home, reducing the need for frequent clinical visits.
North America Holds the Leading Position
North America accounted for 36.70% of the global share in 2025. The region benefits from high menopause awareness, strong healthcare infrastructure, established women’s health services, and widespread availability of treatment options.
The United States remains a major contributor, supported by high healthcare spending, growing adoption of specialized women’s health services, and increasing interest in personalized treatment. Digital consultations and healthcare applications are also improving access to menopause-related care.
Asia Pacific Emerges as the Fastest-Growing Region
Asia Pacific is expected to experience the fastest growth through 2035. Greater awareness of menopause, expanding gynecological services, improving healthcare infrastructure, and rising availability of therapies are supporting regional development.
India is an important contributor because of its large population, expanding healthcare access, increasing menopause awareness, and growing use of online pharmacies. China, Japan, South Korea, and other economies are also strengthening women’s health services and digital healthcare capabilities.
Europe is expected to grow steadily, supported by established healthcare systems, increasing patient awareness, and ongoing research into hormone-based and non-hormonal approaches to GSM management.
Recent Developments
In February 2026, IBSA UK launched Hyaluxelle, a non-hormonal injectable hyaluronic acid treatment for adult women experiencing atrophic symptoms associated with GSM.
In April 2025, the American Urological Association, together with SUFU and AUGS, released its 2025 guideline on genitourinary syndrome of menopause. The guideline provides evidence-based approaches for evaluating and treating symptoms such as dryness, dyspareunia, and urinary problems while emphasizing shared decision-making.
Future Outlook for Genitourinary Syndrome of Menopause Treatment
The future of genitourinary syndrome of menopause treatment is being shaped by greater awareness, personalized care, non-hormonal therapies, advanced devices, digital healthcare, and expanded access through online channels. As more women seek effective solutions for persistent menopausal symptoms, treatment options are becoming broader and more patient-centered.
With the global sector projected to reach approximately USD 3.21 billion by 2035, continued clinical research, product innovation, and improved menopause education are expected to create powerful opportunities for women’s health providers, pharmaceutical companies, and technology developers.
Buy this report: https://www.precedenceresearch.com/checkout/8115
About Us
Healthcare Prism is a dedicated healthcare insights and outreach platform, operating as an extension of Precedence Research. We share relevant perspectives, industry developments, emerging trends, and research-driven insights across the global healthcare sector. Our content is built on the knowledge, research standards, and expertise of Precedence Research, with a focus on making healthcare information clear, accessible, and useful for industry professionals, businesses, researchers, and healthcare stakeholders. Healthcare Prism serves as a focused platform to extend the reach of Precedence Research’s healthcare insights and connect them with a broader professional audience.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Quick Contact:
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04 and +65 31065601
Visit Our Website: Precedence Research – Advisory, Research & Reports